Halozyme Therapeutics, Inc. (LON:0J2O)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 6.01B |
| Revenue (ttm) | 924.61M |
| Net Income (ttm) | 443.01M |
| Shares Out | n/a |
| EPS (ttm) | 3.52 |
| PE Ratio | 13.57 |
| Forward PE | 9.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150 |
| Average Volume | 2,417 |
| Open | 68.05 |
| Previous Close | 68.84 |
| Day's Range | 68.05 - 69.29 |
| 52-Week Range | 47.01 - 79.41 |
| Beta | n/a |
| RSI | 60.21 |
| Earnings Date | Feb 18, 2026 |
About Halozyme Therapeutics
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper... [Read more]
Financial Performance
In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.
Financial numbers in USD Financial StatementsNews
Halozyme Therapeutics Stock Sees Relative Strength Rating
Halozyme Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw) SAN DIEGO , Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced th...
Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade)
Halozyme's acquisition of Elektrofi extends IP into the 2040s, offering optionality but with uncertain long-term revenue durability. Read why HALO stock is a Buy.
Jim Lang Elected to Halozyme's Board of Directors
SAN DIEGO , Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 year...
The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
Investing in Halozyme Therapeutics is a compelling way to gain exposure to the broader healthcare and biotechnology industries.
Halozyme (HALO) Wins Injunction Against Merck in Germany
Halozyme (HALO) Wins Injunction Against Merck in Germany
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda
Munich court halts Merck's Keytruda subcutaneous launch in Germany over Halozyme patent dispute. Read more here.
Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case
The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck ...
Notable Two Hundred Day Moving Average Cross - HALO
In trading on Thursday, shares of Halozyme Therapeutics Inc (Symbol: HALO) crossed below their 200 day moving average of $63.07, changing hands as low as $61.70 per share. Halozyme Therapeutics Inc sh...
Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript
What Makes Halozyme Therapeutics (HALO) a New Buy Stock
Halozyme Therapeutics (HALO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
HC Wainwright & Co. Reiterates Halozyme Therapeutics (HALO) Buy Recommendation
Fintel reports that on November 28, 2025, HC Wainwright & Co. reiterated coverage of Halozyme Therapeutics (NasdaqGS:HALO) with a Buy recommendation. Analyst Price Forecast Suggests 6.50% Upside
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host in...
J&J, Halozyme win FDA traditional nod for Darzalex Faspro in AL amyloidosis
J&J (JNJ) stock and Halozyme Therapeutics (HALO) stock are in focus as their multiple myeloma therapy Darzalex Faspro is granted traditional FDA nod. Read more here.
Goldman Sachs Raises Price Target for Halozyme Therapeutics (HALO) to $56 | HALO Stock News
Goldman Sachs Raises Price Target for Halozyme Therapeutics (HALO) to $56 | HALO Stock News
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP ...
Why I Keep Buying These 10 Incredible Growth Stocks
Some of these companies are firing on all cylinders and trading at lofty valuations. Others face short-term challenges that have them looking like "buy the dip" opportunities.
Merus Licenses ENHANZE Drug Delivery Technology Of Halozyme Therapeutics
(RTTNews) - Monday, Merus N.V. (MRUS) has entered into a global non-exclusive collaboration and license agreement regarding Halozyme Therapeutics, Inc.'s ENHANZE drug delivery technology.
Halozyme (HALO) Enters Collaboration Agreement with Merus
Halozyme (HALO) Enters Collaboration Agreement with Merus
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ -- Merus N.V.
Insider Sell: Bernadette Connaughton Sells Shares of Halozyme Therapeutics Inc (HALO)
Insider Sell: Bernadette Connaughton Sells Shares of Halozyme Therapeutics Inc (HALO)
Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead?
A Relative Strength Rating upgrade for Halozyme Therapeutics shows improving technical performance.
The Big 3: OKLO, HALO, V
Mike Shorr with @ProsperTradingAcademy is mostly bullish on today's Big 3. He expects explosive price action to happen after Oklo Inc.'s (OKLO) earnings on Tuesday and sees Halozyme Therapeutics (HALO...